Financial Daily from THE HINDU group of publications
Wednesday, Jul 28, 2004
Financial Daily from THE HINDU group of publications Wednesday, Jul 28, 2004 |
||
|
|
||
|
Corporate
-
Announcements Industry & Economy - Health NPIL gets India rights for Dobutrex Our Bureau
Mumbai , July 27 DRUG major Nicholas Piramal India Ltd (NPIL) has acquired the India rights for cardiac stimulant brand Dobutrex, from Eli Lily & Company of the US. Though financial details of the acquisition remain undisclosed, NPIL officials told Business Line that Dobutrex had clocked sales of Rs 6.3 crore in 2003. Dobutrex is an injectible cardiac stimulant used in situations such as heart attack and the drug has a 37 per cent market share in the local market, a company source said. The size of the cardiac stimulant market is estimated at Rs 17 crore, he added. Meanwhile, an Eli Lilly official said that the company sold Dobutrex since it wanted to focus on its products in niche segments.
More Stories on : Announcements | Health | Pharmaceuticals
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2004, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|